DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...
DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback